Current and emerging investigational venetoclax-based therapies in chronic lymphocytic leukemia

Introduction: Venetoclax has emerged as a breakthrough treatment which revolutionized the therapeutic paradigm of chronic lymphocytic leukemia (CLL). This is primarily attributed to efficacy venetoclax time-limited, chemo-free, therapy in field dominated by targeted agents given on continuous schedule. Furthermore, compelling clinical data support use combination with other hope preventing drug resistance due emergence acquired mutations.Areas covered: paper provides an overview results newly approved or investigational venetoclax-based therapies for CLL. In view current and potential roles CLL care, strengths disadvantages venetoclax-combinations are discussed. The MEDLINE database, ClinicalTrials.gov conference proceedings were all reviewed select relevant literature.Expert opinion: While advent combinations significantly expanded options patients CLL, further research longer follow-up required address remaining open questions such (I) role fixed duration therapy(II) timing threshold minimal residual disease (MRD) assessment discontinuation, (III) novel triplet backbone therapy, (IV) indications re-initiation venetoclax.